OTCMKTS:CLXPF

Cybin (CLXPF) News Today

$0.55

-0.03 (-5.20%)

(As of 09/27/2023 ET)

Compare

Today's Range: $0.50
▼
$0.62
50-Day Range: $0.30
▼
$0.63
52-Week Range: $0.49
▼
$3.38

Volume: 6.60 million shs
Average Volume: 551,962 shs
Market Capitalization: $81.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines Short Interest

Source

Source	Headline
	Cybin (OTCMKTS:CLXPF) Shares Up 39.4% americanbankingnews.com - September 19 at 2:30 AM
	Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs finance.yahoo.com - September 14 at 10:17 AM
	Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment benzinga.com - January 16 at 5:07 PM
	Cybin Provides Update on its Intellectual Property Portfolio - Business Wire businesswire.com - October 6 at 9:57 AM
	Cybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - Benzinga benzinga.com - October 4 at 1:23 AM
	Mindset Pharma says licensing agreement with Cybin gives it multiple 'shots for the goal' - Proactive Investors USA proactiveinvestors.com - September 29 at 8:53 PM
	Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family benzinga.com - September 27 at 2:49 PM
	NA Proactive news snapshot: Nevada Copper, Mindset Pharma, EverGen Infrastructure, Psyched Wellness, BetterLife Pharma, Endexx, Group Eleven Resources... - Proactive Investors USA proactiveinvestors.com - September 27 at 12:49 PM
	Cybin to Participate in Upcoming Scientific and Investor Conferences - Business Wire businesswire.com - September 21 at 11:12 AM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks 'Tremendous' Milestone as First Participants Receive Initial CYB003 Dose - StreetInsider.com streetinsider.com - September 21 at 1:11 AM
	Cybin Achieves Research and Development Milestones Ahead of Projected Timelines - Business Wire businesswire.com - September 20 at 3:10 PM
	First Africa Cannabis SPAC to Go Ahead With Cilo Cybin Listing - Bloomberg bloomberg.com - September 9 at 3:23 AM
	COMP SERVICES (CMPS), (CSE:OPTI) – Psychedelics May Make People Less Afraid of Death - Benzinga benzinga.com - September 7 at 4:11 PM
	7 Psychedelics Stocks to Buy for a Big Drug Boom - Nasdaq nasdaq.com - September 1 at 6:55 PM
	Cybin makes positive progress towards its goal of advancing psychedelics to therapeutics - Proactive Investors USA proactiveinvestors.com - September 1 at 6:55 PM
	(ALID), ATA (ATAI), (BMNDF), COMP SERVICES (CMPS), Cybin Inc. Common Shares (CYBN), Small Pharma (DMTTF), - Benzinga benzinga.com - August 31 at 10:55 PM
	Cybin Inc. Common Shares (CYBN) – Cybin Announces Final Adelia Milestone Achievement - Benzinga benzinga.com - August 31 at 9:30 AM
	Cybin Announces Final Adelia Milestone Achievement - Business Wire businesswire.com - August 31 at 9:30 AM
	Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Yahoo Finance finance.yahoo.com - August 30 at 9:04 PM
	Wellbeing' CEO Joins Benzinga's Psychedelic Advisory Board - Business Wire businesswire.com - August 30 at 10:58 AM
	BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD - StreetInsider.com streetinsider.com - August 30 at 10:58 AM
	Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business Wire businesswire.com - August 30 at 10:58 AM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector - StreetInsider.com streetinsider.com - August 26 at 2:45 PM
	Stifel analysts still bullish on psychedelic stocks, citing attractive risk-reward profile - Proactive Investors USA proactiveinvestors.com - August 24 at 9:14 PM
	MDD - Latest News and breaking headlines - Benzinga benzinga.com - August 17 at 4:17 PM
	Cybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depressive Disorder - Marketscreener.com marketscreener.com - August 17 at 4:17 PM
	PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders - StreetInsider.com streetinsider.com - August 17 at 11:17 AM
	2022-08-17 \| NEO:CYBN \| Press Release \| Cybin Inc. - Stockhouse stockhouse.com - August 17 at 11:17 AM
	BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression benzinga.com - August 17 at 8:37 AM
	Filament Health : Q2 MD&A - Marketscreener.com marketscreener.com - August 16 at 3:15 PM
	Launched Pre-COVID, A Psychedelics Company Finds Its Sweet Spot In Being –And Staying- Remote - Forbes forbes.com - August 15 at 11:35 AM
	This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares benzinga.com - August 9 at 6:12 PM
	PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program - StreetInsider.com streetinsider.com - August 4 at 5:06 AM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants - StreetInsider.com streetinsider.com - July 28 at 7:22 PM
	Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders - StreetInsider.com streetinsider.com - July 28 at 4:19 AM
	Cybin Announces Date of Annual Meeting of Shareholders - Yahoo Finance finance.yahoo.com - July 26 at 10:52 AM
	Cybin Announces Date of Annual Meeting of Shareholders - Business Wire businesswire.com - July 25 at 7:11 PM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study - StreetInsider.com streetinsider.com - July 25 at 2:11 PM
	Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical - Business Wire businesswire.com - July 11 at 8:31 AM
	Cybin gets FDA green light to begin clinical trial of psilocybin candidate for depression - Seeking Alpha seekingalpha.com - June 27 at 8:40 PM
	Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder - Business Wire businesswire.com - June 27 at 10:12 AM
	Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022 - Yahoo Finance finance.yahoo.com - June 16 at 10:59 AM
	Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder - Business Wire businesswire.com - June 9 at 5:56 PM
	Cybin Acquires DMT Clinical Study from Entheon Biomedical - Business Wire businesswire.com - June 7 at 10:45 AM
	2022-06-03 \| NEO:CYBN \| Press Release \| Cybin Inc. - Stockhouse stockhouse.com - June 3 at 1:03 PM
	Five Next-Gen Psychedelics Clinical Trials Taking Place in 2022 - StreetInsider.com streetinsider.com - June 2 at 4:42 PM
	Cybin submits application for trial of psilocybin-based CYB003 to treat depression - Seeking Alpha seekingalpha.com - June 2 at 4:42 PM
	Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy - Business Wire businesswire.com - June 2 at 4:42 PM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine's Effects on the Brain - StreetInsider.com streetinsider.com - May 31 at 12:53 PM
	Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds - StreetInsider.com streetinsider.com - May 26 at 5:38 PM

Get Cybin News Delivered to You Automatically

CLXPF Media Mentions By Week

CLXPF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLXPF
News Sentiment
▼
0.00

0.80
▲
Average
Medical
News Sentiment

CLXPF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLXPF Articles
This Week
▼
0

0
▲
CLXPF Articles
Average Week

Get Cybin News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (OTCMKTS:CLXPF) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cybin (CLXPF) News Today

CLXPF Media Mentions By Week

CLXPF Media Sentiment

CLXPF News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info